An interesting response to diphencyprone (DPC) sensitization on facial warts: review of DPC treatment for viral warts

Pollock, Beatrice; Highet, AS

doi:10.1080/095466302317584386

Cited by 21 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cytokines may encourage the host's immune reaction to the wart by activating the function of natural killer (NK) cells. Thus, they activate NK cells to lyse virus‐infected cells, leading to cell death …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Investigations of the efficacy of diphenylcyclopropenone immunotherapy for the treatment of warts

2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Thus, they activate NK cells to lyse virus-infected cells, leading to cell death. 17 This study was limited by its status as a single-arm, uncontrolled, open-label study. Because we did not use a control group, we cannot exclude the possibility that warts in some of our patients may have cleared by chance during the course of treatment.…”

Section: Discussionmentioning

confidence: 99%

Investigations of the efficacy of diphenylcyclopropenone immunotherapy for the treatment of warts

2014

View full text Add to dashboard Cite

show abstract

“…Contact immunotherapy might function through the induction of a type IV hypersensitivity response in papilloma virus‐infected tissue, leading to wart destruction. Precise immunologic mechanisms are unclear but probably involve a nonspecific, cell‐mediated process triggered by the immune stimulus . For treatment with contact immunotherapy, acquisition of sensitization is necessary and can be identified by local reactions, such as the EBI and the PI, after the application of contact sensitizers .…”

Section: Discussionmentioning

confidence: 99%

Factors contributing to the treatment duration of diphenylcyclopropenone immunotherapy for periungual warts

Park

Kim

2015

Dermatologic Therapy

View full text Add to dashboard Cite

Diphenylcyclopropenone (DPCP) immunotherapy has been shown to be efficacious for the treatment of warts, especially periungual warts for which destructive techniques are limited. However, factors affecting the duration of treatment of periungual warts have not been studied. A total of 61 patients with periungual warts who were completely cured with DPCP immunotherapy were included in this study. Age, sex, disease duration, location (fingernail, toenail, or both), number of warts, diameter of the largest wart, application number for sensitization and two types of sensitization reactions, erythema and blister index (EBI), and pruritus index were evaluated. Multiple linear regression analysis was performed to find correlations of these variables with the treatment duration. Of the nine variables, application number for sensitization (regression coefficient = 3.251 and 2.428, respectively) and EBI (regression coefficient = -9.950 and -9.694, respectively) were independent factors significantly affecting both the total duration of treatment and the duration of treatment after sensitization (p < 0.05, respectively). The sample size was limited. A shorter sensitization period and more severe EBI of the sensitization reaction contribute to a shorter time required for a complete cure in the treatment of periungual warts with DPCP immunotherapy.

show abstract

“…It is theorized that the sensitizing agent acts as a hapten, which interacts with tumor antigens that otherwise do not provoke an effective immune response. Another hypothesis is that hapten elicitation results in a strong local Th1 immune response, with resultant nonspecific damage to nearby 'innocent bystander' HPVinfected epithelial cells [89]. Although their underlying mechanisms and historical values are of interest, these treatments are currently not considered reliable in comparison to other available treatment modalities.…”

Section: Other Topical and Locally Acting Antineoplastic Agentsmentioning

confidence: 99%

Topical Antineoplastic Agents in the Treatment of Mucocutaneous Diseases

Grossberg

Gaspari

2011

Topical Applications and the Mucosa

View full text Add to dashboard Cite

Topical antineoplastic agents have a well-established role in the treatment of several dermatological conditions. Their use in the treatment of mucosal skin disease also has gained increasing recognition. Topical 5-fluorouracil (5-FU), an antimetabolite, and imiquimod, an immunomodulatory agent with antitumor properties, are the two principal topical antineoplastic agents used in the treatment of mucocutaneous diseases. Although the vast majority of their mucosal uses are currently not approved by the Federal Drug Administration, there are numerous case series, open-label studies and randomized controlled trials supporting their uses in the treatment of mucocutaneous diseases. Both topical 5-FU and imiquimod have been successfully utilized in the treatment of a wide range of mucosal diseases, including actinic cheilitis, Bowen's disease of the anal and vulvar mucosa, and genital and perianal condyloma. Reports of their uses in the treatment of mucocutaneous diseases indicate that these agents can be safely administered, though adverse effects such as local inflammation may be augmented when these agents are applied to mucosal surfaces. Additionally, locally acting intralesional chemotherapeutic agents, such as bleomycin and interferon, have well-defined applications in the treatment of mucosal skin diseases such as condyloma acuminata. As further studies are conducted, these topical and intralesional neoplastic agents, in addition to emerging agents that are in various stages of development, such as Toll-like receptor 9 agonists and ingenol mebutate, may play an increasingly important role in the future treatment of mucocutaneous diseases.

show abstract

An interesting response to diphencyprone (DPC) sensitization on facial warts: review of DPC treatment for viral warts

Abstract: DPC appears to be a valuable, safe and well-tolerated treatment for resistant viral warts and can be considered as a first line treatment. We review its use and action in this paper

Cited by 21 publications

References 13 publications

Investigations of the efficacy of diphenylcyclopropenone immunotherapy for the treatment of warts

Investigations of the efficacy of diphenylcyclopropenone immunotherapy for the treatment of warts

Factors contributing to the treatment duration of diphenylcyclopropenone immunotherapy for periungual warts

Topical Antineoplastic Agents in the Treatment of Mucocutaneous Diseases

Contact Info

Product

Resources

About